HRP20191121T1 - Tretman multiple skleroze - Google Patents
Tretman multiple skleroze Download PDFInfo
- Publication number
- HRP20191121T1 HRP20191121T1 HRP20191121TT HRP20191121T HRP20191121T1 HR P20191121 T1 HRP20191121 T1 HR P20191121T1 HR P20191121T T HRP20191121T T HR P20191121TT HR P20191121 T HRP20191121 T HR P20191121T HR P20191121 T1 HRP20191121 T1 HR P20191121T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- multiple sclerosis
- benzyloxy
- cyclopropyl
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382310 | 2015-06-12 | ||
| EP15382369 | 2015-07-17 | ||
| PCT/EP2016/063368 WO2016198649A1 (en) | 2015-06-12 | 2016-06-10 | Biomarkers associated with lsd1 inhibitors and uses thereof |
| EP17735004.8A EP3307267B1 (en) | 2016-06-10 | 2017-06-09 | Multiple sclerosis treatment |
| PCT/EP2017/064206 WO2017212061A1 (en) | 2015-06-12 | 2017-06-09 | Method of treating multiple sclerosis employing a lsd1-inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191121T1 true HRP20191121T1 (hr) | 2019-09-20 |
Family
ID=56345081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191121TT HRP20191121T1 (hr) | 2015-06-12 | 2017-06-09 | Tretman multiple skleroze |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20180284095A1 (enExample) |
| EP (1) | EP3307909A1 (enExample) |
| JP (3) | JP6855466B2 (enExample) |
| KR (2) | KR20180011331A (enExample) |
| CN (2) | CN107849611A (enExample) |
| AU (2) | AU2016275702A1 (enExample) |
| BR (1) | BR112018075310A2 (enExample) |
| CA (1) | CA2987876A1 (enExample) |
| CY (1) | CY1121988T1 (enExample) |
| DK (1) | DK3307267T3 (enExample) |
| HR (1) | HRP20191121T1 (enExample) |
| HU (1) | HUE043954T2 (enExample) |
| IL (2) | IL256208A (enExample) |
| LT (1) | LT3307267T (enExample) |
| MX (2) | MX2017015922A (enExample) |
| MY (1) | MY190849A (enExample) |
| PT (1) | PT3307267T (enExample) |
| RU (1) | RU2768120C2 (enExample) |
| SG (1) | SG10201911989SA (enExample) |
| SM (1) | SMT201900353T1 (enExample) |
| TR (1) | TR201909353T4 (enExample) |
| WO (2) | WO2016198649A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| KR20180011331A (ko) * | 2015-06-12 | 2018-01-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제와 관련된 바이오마커 및 그의 용도 |
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| SI3307267T1 (sl) | 2016-06-10 | 2019-08-30 | Oryzon Genomics, S.A. | Zdravljenje multiple skleroze |
| JP2019128317A (ja) * | 2018-01-26 | 2019-08-01 | 学校法人同志社 | 多発性硬化症の診断マーカー又は診断キット |
| WO2019211491A1 (en) * | 2018-05-04 | 2019-11-07 | Oryzon Genomics, S.A. | Stable pharmaceutical formulation |
| SI3941466T1 (sl) | 2019-03-20 | 2026-04-30 | Oryzon Genomics, S.A. | Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje |
| EP4024049A4 (en) * | 2019-12-19 | 2023-09-20 | Daegu Gyeongbuk Institute Of Science and Technology | BIOMARKER COMPOSITION FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING NASAL FLUID SAMPLE AND METHOD FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING SAME |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0833901A1 (en) * | 1995-06-07 | 1998-04-08 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics using transgenic animal models |
| EP1193261A1 (en) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| EP1940773B1 (en) | 2005-08-10 | 2015-03-18 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| EP2142287A4 (en) | 2007-04-13 | 2012-05-23 | Univ Johns Hopkins | INHIBITORS OF LYSINPECIFIC DEMETHYLASE |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8895526B2 (en) * | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) * | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| AU2010284221B2 (en) | 2009-08-18 | 2016-09-22 | Casero, Robert A | (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| US8765820B2 (en) | 2010-04-20 | 2014-07-01 | Universita Degli Studi Di Roma “La Sapienza” | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| DK2598482T3 (en) * | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| MX347913B (es) | 2011-03-25 | 2017-05-17 | Glaxosmithkline Intellectual Property (No 2) Ltd | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina. |
| BR112014002939A2 (pt) | 2011-08-09 | 2017-03-01 | Takeda Pharmaceuticals Co | composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1 |
| AU2012296639B2 (en) | 2011-08-15 | 2016-06-09 | University Of Utah Research Foundation | Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP2907802B1 (en) | 2012-10-12 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| US9918983B2 (en) | 2013-05-30 | 2018-03-20 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells |
| CN105555784B (zh) | 2013-06-19 | 2019-03-15 | 犹他大学研究基金会 | 作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物 |
| CN103319466B (zh) | 2013-07-04 | 2016-03-16 | 郑州大学 | 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用 |
| JP6521967B2 (ja) | 2013-08-06 | 2019-05-29 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
| CA3161836A1 (en) | 2013-12-11 | 2015-06-18 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| WO2015120281A1 (en) | 2014-02-07 | 2015-08-13 | Musc Foundation For Research Development | Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
| NZ725262A (en) | 2014-04-11 | 2023-01-27 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
| WO2015168466A1 (en) | 2014-05-01 | 2015-11-05 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| MX375102B (es) | 2014-05-30 | 2025-03-06 | Ieo St Europeo Di Oncologia S R L | Compuestos de ciclopropilamina como inhibidores de histona demetilasa |
| PL3160956T3 (pl) | 2014-06-27 | 2020-11-30 | Celgene Quanticel Research, Inc. | Inhibitory demetylazy-1 specyficznej dla lizyny |
| CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| EA201790082A1 (ru) | 2014-07-03 | 2017-08-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической демитилазы-1 |
| WO2016003917A1 (en) | 2014-07-03 | 2016-01-07 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| ES2935114T3 (es) | 2014-09-05 | 2023-03-01 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| KR20180011331A (ko) * | 2015-06-12 | 2018-01-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제와 관련된 바이오마커 및 그의 용도 |
-
2016
- 2016-06-10 KR KR1020187001221A patent/KR20180011331A/ko not_active Withdrawn
- 2016-06-10 WO PCT/EP2016/063368 patent/WO2016198649A1/en not_active Ceased
- 2016-06-10 JP JP2018516634A patent/JP6855466B2/ja not_active Expired - Fee Related
- 2016-06-10 MX MX2017015922A patent/MX2017015922A/es unknown
- 2016-06-10 EP EP16734564.4A patent/EP3307909A1/en not_active Withdrawn
- 2016-06-10 CA CA2987876A patent/CA2987876A1/en not_active Abandoned
- 2016-06-10 CN CN201680045398.8A patent/CN107849611A/zh active Pending
- 2016-06-10 AU AU2016275702A patent/AU2016275702A1/en not_active Abandoned
- 2016-06-10 SG SG10201911989SA patent/SG10201911989SA/en unknown
- 2016-06-10 US US15/735,377 patent/US20180284095A1/en not_active Abandoned
-
2017
- 2017-06-09 DK DK17735004.8T patent/DK3307267T3/da active
- 2017-06-09 CN CN201780002630.4A patent/CN107921029B/zh not_active Expired - Fee Related
- 2017-06-09 BR BR112018075310-6A patent/BR112018075310A2/pt not_active Application Discontinuation
- 2017-06-09 MX MX2017015921A patent/MX2017015921A/es active IP Right Grant
- 2017-06-09 AU AU2017277751A patent/AU2017277751B2/en not_active Ceased
- 2017-06-09 SM SM20190353T patent/SMT201900353T1/it unknown
- 2017-06-09 KR KR1020187001123A patent/KR102372194B1/ko not_active Expired - Fee Related
- 2017-06-09 TR TR2019/09353T patent/TR201909353T4/tr unknown
- 2017-06-09 RU RU2019100037A patent/RU2768120C2/ru active
- 2017-06-09 PT PT17735004T patent/PT3307267T/pt unknown
- 2017-06-09 LT LTEP17735004.8T patent/LT3307267T/lt unknown
- 2017-06-09 HU HUE17735004A patent/HUE043954T2/hu unknown
- 2017-06-09 HR HRP20191121TT patent/HRP20191121T1/hr unknown
- 2017-06-09 JP JP2017565305A patent/JP6411680B1/ja not_active Expired - Fee Related
- 2017-06-09 WO PCT/EP2017/064206 patent/WO2017212061A1/en not_active Ceased
- 2017-06-09 MY MYPI2017001810A patent/MY190849A/en unknown
- 2017-12-10 IL IL256208A patent/IL256208A/en unknown
- 2017-12-10 IL IL256207A patent/IL256207B/en unknown
-
2018
- 2018-09-21 JP JP2018177879A patent/JP2019023202A/ja active Pending
-
2019
- 2019-06-26 CY CY20191100663T patent/CY1121988T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3426250T3 (pl) | Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4 | |
| JP2016518337A5 (enExample) | ||
| CY1121988T1 (el) | Θεραπευτικη αγωγη της πολλαπλης σκληρυνσης | |
| EP3267995A4 (en) | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF FIBROSIS | |
| PL3805233T3 (pl) | ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego | |
| MA52252A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
| IL279810A (en) | Heteroaryl-converted sulfonamide compounds and their use as medicinal agents | |
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| DK3381451T3 (da) | Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| EP3430400A4 (en) | DOSAGE PLANS FOR THE TREATMENT OF FUNGI INFECTIONS | |
| SMT202400271T1 (it) | Composizione farmaceutica per l’uso nel trattamento o nella prevenzione di una patologia correlata a c5 | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| EP3848022C0 (en) | THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION | |
| EP3645120A4 (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION | |
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
| EP3313380A4 (en) | COMPOSITION FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES TO AN ANIMAL | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| PL3124048T3 (pl) | Kompozycja do stosowania doustnego w leczeniu choroby lub dolegliwości związanych z odpływem żołądkowo-przełykowym | |
| IL286818A (en) | Mirikizumab for use in a method of treating crohns disease | |
| HUE066609T2 (hu) | Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra | |
| EP3399973A4 (en) | ON FOOD BASED RELEASE OF A THERAPEUTIC FOR THE TREATMENT OF HEPATIC ENZEPHALOPATHY | |
| HRP20251502T1 (hr) | Kontinuirana primjena farmaceutskog pripravka za liječenje neurodegenerativnih poremećaja | |
| MA39833A (fr) | Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide |